Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis

Conclusion The results of the present meta-analysis have confirmed the role of the CALR mutation in the diagnosis of, and as a prognostic tool for, PMF. Our results suggest that patients with the CALR mutation will have better overall survival than patients with the JAK2 mutation in a non-Asian population. Micro-Abstract Calreticulin (CALR) is a recently discovered mutation in patients with primary myelofibrosis (PMF). Six studies (Asian and non-Asian) met the inclusion criteria for the present meta-analysis, which has confirmed the role of the CALR mutation in the diagnosis of, and as a prognostic tool for, PMF. Our results suggest that patients with CALR mutation have better overall survival than patients with janus kinase 2 (JAK2) mutation in a non-Asian population.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research